Barclays
BVS icon

Barclays’s Bioventus BVS Stock Holding History

Barclays’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$515K Sell
37,776
-16,942
-31% -$223K ﹤0.01% 3455
2026
Q2 		$517K Sell
54,718
-10,077
-16% -$96.2K ﹤0.01% 3206
2026
Q1 		$592K Sell
64,795
-27,728
-30% -$233K ﹤0.01% 3085
2025
Q4 		$688K Buy
92,523
+26,547
+40% +$191K ﹤0.01% 3676
2025
Q3 		$441K Sell
65,976
-22,132
-25% -$154K ﹤0.01% 3890
2025
Q2 		$583K Buy
88,108
+41,032
+87% +$291K ﹤0.01% 3679
2025
Q1 		$431K Sell
47,076
-19,261
-29% -$192K ﹤0.01% 3617
2024
Q4 		$697K Buy
66,337
+15,683
+31% +$185K ﹤0.01% 3623
2024
Q3 		$605K Buy
50,654
+9,854
+24% +$85.2K ﹤0.01% 3657
2024
Q2 		$235K Buy
40,800
+6,498
+19% +$35.6K ﹤0.01% 3495
2024
Q1 		$178K Sell
34,302
-25,290
-42% -$124K ﹤0.01% 4179
2023
Q4 		$314K Buy
59,592
+23,522
+65% +$93.1K ﹤0.01% 4171
2023
Q3 		$119K Buy
+36,070
New +$127K ﹤0.01% 3533
2023
Q2 		– Sell
-18,524
Closed -$19.8K – 4590
2023
Q1 		$19.8K Buy
18,524
+9,945
+116% +$19K ﹤0.01% 4661
2022
Q4 		$22.4K Buy
8,579
+7,239
+540% +$31.6K ﹤0.01% 4783
2022
Q3 		$9K Sell
1,340
-246
-16% -$1.93K ﹤0.01% 4344
2022
Q2 		$11K Sell
1,586
-2,967
-65% -$30.3K ﹤0.01% 4591
2022
Q1 		$65K Sell
4,553
-29,475
-87% -$395K ﹤0.01% 3994
2021
Q4 		$493K Buy
34,028
+27,465
+418% +$390K ﹤0.01% 3209
2021
Q3 		$93K Buy
6,563
+5,510
+523% +$84.8K ﹤0.01% 3932
2021
Q2 		$19K Sell
1,053
-6,509
-86% -$105K ﹤0.01% 4504
2021
Q1 		$116K Buy
+7,562
New +$108K ﹤0.01% 3939

Other funds holding BVS

Essex Woodlands Management
Essex Woodlands Management The Woodlands, Texas $323M AUM 25.39% 1-Year Est. Return
Royce & Associates
Royce & Associates New York $11B AUM 39.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
TAM
Telemark Asset Management Boston, Massachusetts $1.39B AUM 81.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $113B AUM 26.61% 1-Year Est. Return
Knights of Columbus Asset Advisors
Knights of Columbus Asset Advisors New Haven, Connecticut $2.01B AUM 34.13% 1-Year Est. Return

Barclays's BVS Position: Q3 2026 in Review

Barclays reduced its Bioventus (BVS) stake by 31% in Q3 2026, selling an estimated $223K and leaving 37,776 shares worth $515K. The position accounts for ﹤0.01% of the portfolio, ranked #3455.

Barclays first reported a position in BVS in Q1 2021 and has held it in 22 quarters since. The position peaked at $697K in Q4 2024. 81 funds tracked by Wall St. Rank hold BVS as of Q3 2026.

  • Barclays held 37,776 shares of Bioventus worth $515K as of Q3 2026.
  • Barclays sold 16,942 Bioventus shares in Q3 2026, an estimated $223K.
  • Bioventus made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3455 holding.
  • Barclays first reported a position in Bioventus in Q1 2021 and has held it in 22 quarters since.
  • Barclays's Bioventus position peaked at $697K in Q4 2024.
  • 81 funds tracked by Wall St. Rank held Bioventus as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.